Potential cost-effectiveness of colorectal cancer chemoprevention with nonsteroidal anti-inflammatory drugs

References

• Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer 1 Clin. 53(1), 5–26 (2003).
   Google Scholar
• Winawer S, Fletcher R, Rex D et al Colorectal cancer screening and surveillance: clinical guidelines and rationale — update based on new evidence. Castroenterology124(2), 544–560 (2003).
   PubMed Web of Science ®Google Scholar
• ••Most recent recommendations regardingcolorectal cancer screening and surveillance with a review of the literature.
   Google Scholar
• Boland CR. Malignant tumors of the colon. In: Textbook of Gastroenterology Fourth Edition. Yamada T (Ed.). Lippincott Williams & Wilkins, NY, USA, 1940-1990 (2003).
   Google Scholar
• Calvert PM, Frucht H. The genetics of colorectal cancer. Ann Intern. Merl 137(7), 603–612 (2002).
   Google Scholar
• Burt RVV. Colon cancer screening. Castroenterology119(3), 837–853 (2000).
   PubMed Web of Science ®Google Scholar
• Levin B. Potential pitfalls in the use of surrogate end points in colorectal adenoma chemoprevention. j Natl Cancer Inst. 95(10), 697–699 (2003).
   Google Scholar
• Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61(5), 759–767 (1990).
   PubMed Web of Science ®Google Scholar
• SEER Cancer Statistics Review, 1973–1994. NIH Pub. No. 97–2789. Ries LAG, Kosary CL, Hankey BF, Miller BA, Harras A, Edwards BK (Eds). National Cancer Institute, ND, USA (1997).
   Google Scholar
• Ransohoff DF, Sandler RS. Clinical practice. Screening for colorectal cancer. N &igLj Med 346(1), 40–44 (2002).
   PubMed Web of Science ®Google Scholar
• Mandel JS, Church TR, Bond JH et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl. J. Med. 343(22), 1603–1607 (2000).
   Google Scholar
• Hardcastle JD, Chamberlain JO, Robinson MH et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348(9040), 1472–1477 (1996).
   PubMed Web of Science ®Google Scholar
• Kronborg 0, Fenger C, Olsen J, Jorgensen OD, Sondergaard 0. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348(9040), 1467–1471 (1996).
   Google Scholar
• Jorgensen OD, Kronborg 0, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 50(1), 29–32 (2002).
   Google Scholar
• Mandel JS, Bond JH, Church TR etal. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl. J. Med 328(19), 1365–1371 (1993).
   Google Scholar
• Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl. J. Merl 326(10), 653–657 (1992).
   Google Scholar
• Winawer SJ, Zauber AG, Ho MN etal. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl. J. Med 329(27), 1977-1981 (1993).
   Google Scholar
• Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Co-operative Study Group 380. N Engl. J. Med. 343(3), 162–168 (2000).
   Google Scholar
• Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DE Results of screening colonoscopy among persons 40 to 49 years of age. NEngLJ Med 346(23), 1781–1785 (2002).
   Google Scholar
• Lieberman DA, Weiss DG, Harford WV et al One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon N. Engl. Med 345(8), 555–560 (2001).
   PubMed Web of Science ®Google Scholar
• Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 137(2), 132–141 (2002).
   PubMed Web of Science ®Google Scholar
• ••Review of the literature regardingcolorectal cancer screening.
   Google Scholar
• Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick AM. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann. Intern. Med 135(9), 769–781 (2001).
   Google Scholar
• •Cost-effectiveness analysis of chemoprevention with aspirin in average risk individuals, as an adjunct or substitute for screening.
   Google Scholar
• Ladabaum U, Scheiman JM, Fendrick AM. Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis. Am.j Med. 114 (7), 546–554 (2003).
   Google Scholar
• •Cost-effectiveness analysis of chemoprevention with cyclooxygenase-2-specific inhibitors as an adjunct or substitute for screening in individuals at average or elevated risk of colorectal cancer due to a family history of the disease.
   Google Scholar
• Colorectal cancer test use among persons aged 50 years or over — United States, 2001. MMWR 52 (10), 193–196 (2003).
   Google Scholar
• Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. j Nall Cancer Inst. 94(4), 252–266 (2002).
   PubMed Web of Science ®Google Scholar
• ••Review of the potential of nonsteroidalanti-inflammatory drugs for cancer chemoprevention.
   Google Scholar
• FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl. J. Med. 345(6), 433–442 (2001).
   Google Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl. J. Med 340(24), 1888–1899 (1999).
   Google Scholar
• Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann. Intern Med 136(2), 161–172 (2002).
   PubMed Web of Science ®Google Scholar
• Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long-term use of aspirin: meta-analysis. BE Med J. 321 (7270), 1183–1187 (2000).
   Google Scholar
• Silverstein FE, Faich G, Goldstein JL etal Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAIVIA 284(10), 1247–1255 (2000).
   Google Scholar
• Bombardier C, Lame L, Reicin A et al Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. NEngLJ Med 343(21), 1520–1528 (2000).
   PubMed Web of Science ®Google Scholar
• Peleg, II, Wilcox CM. The role of eicosanoids, cyclooxygenases and nonsteroidal anti-inflammatory drugs in colorectal tumorigenesis and chemoprevention. j Clin. Gastroenterol 34(2), 117–125 (2002).
   Google Scholar
• ••Review of the potential of nonsteroidalanti-inflammatory drugs for cancer chemoprevention.
   Google Scholar
• Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis and colon-cancer chemoprevention. Lancet awl 3(3), 166–174 (2002).
   PubMedGoogle Scholar
• ••Review of the molecular mechanisms ofcancer chemoprevention by nonsteroidal anti-inflammatory drugs.
   Google Scholar
• Huts G, Koomstra JJ, Kleibeuker JH. Nonsteroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 362 (9379), 230–232 (2003).
   PubMedGoogle Scholar
• Ricchi P, Zarrilli R, Di Palma A, Acquaviva AM. Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. BE j Cancer88(6), 803–807 (2003).
   Google Scholar
• Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Upregulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (4), 1183–1188 (1994).
   Google Scholar
• Sandler RS, Halabi S, Baron JA etal A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl. J. Med 348(10), 883–890 (2003).
   Google Scholar
• ••Randomized trial of aspirin chemoprevention of adenomas in patients with a history of colorectal cancer.
   Google Scholar
• Baron JA, Cole BF, Sandler RS eta]. A randomized trial of aspirin to prevent colorectal adenomas. N Engl. J. Med 348(10), 891–899 (2003).
   Google Scholar
• ••Randomized trial of aspirinchemoprevention of adenomas.
   Google Scholar
• Benamouzig R, Deyra J, Martin A eta]. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125(2), 328–336 (2003).
   PubMed Web of Science ®Google Scholar
• •Randomized trial of aspirin chemoprevention of adenomas.
   Google Scholar
• Labayle D, Fischer D, Vielh P etal. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101 (3), 635–639 (1991).
   PubMedGoogle Scholar
• Nugent 1Q, Farmer KC, Spigelman AD, Williams CB, Phillips RIK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. BE J. Sorg. 80(12), 1618–1619 (1993).
   Google Scholar
• Giardiello FM, Hamilton SR, Krush AJ eta]. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl. J. Med 328(18), 1313–1316 (1993).
   Google Scholar
• Giardiello FM, Yang VW, Hylind LM et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N EngLJ Med. 346 (14), 1054–1059 (2002).
   Google Scholar
• Steinbach G, Lynch PM, Phillips RK etal The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J. Med 342 (26), 1946-1952 (2000).
   Google Scholar
• Ladenheim J, Garcia G, Titzer D etal Effect of sulindac on sporadic colonic polyps. Gastroenterology108(4), 1083–1087 (1995).
   PubMedGoogle Scholar
• Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl Med 321(3), 129–135 (1989).
   PubMedGoogle Scholar
• Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann. Intern. Med. 128(9), 713–720 (1998).
   Google Scholar
• Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH. Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand. Gastroenterol. 34(4), 414–420 (1999).
   Google Scholar
• Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology122(1), 78–84 (2002).
   PubMedGoogle Scholar
• •Cost-effectiveness analysis of chemoprevention with aspirin.
   Google Scholar
• Hawkey C, Lame L, Simon T eta]. Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum. 43(2), 370–377 (2000).
   Google Scholar
• Goldstein JL, Silverstein FE, Agrawal NM etal Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am j Gastmenterol 95(7), 1681–1690 (2000).
   Google Scholar
• Arguedas MR, Heudebert GR, Wilcox CM. Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis. Aliment Pharmacol. Therapeut. 15(5), 631–638 (2001).
   Google Scholar
• •Cost-effectiveness analysis of chemoprevention with cyclooxygenase-2-specific inhibitors in patients who have had polypectomy.
   Google Scholar